Biocept, Inc.
BIOCQ
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 589.00K | 673.00K | -913.00K | 1.01M | 5.82M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 589.00K | 673.00K | -913.00K | 1.01M | 5.82M |
| Cost of Revenue | 2.55M | 3.03M | 4.31M | 5.78M | 8.02M |
| Gross Profit | -1.96M | -2.36M | -5.22M | -4.77M | -2.20M |
| SG&A Expenses | 3.74M | 3.70M | 3.35M | 4.02M | 5.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.70M | 7.77M | 8.88M | 11.16M | 15.71M |
| Operating Income | -6.11M | -7.10M | -9.79M | -10.16M | -9.89M |
| Income Before Tax | -3.63M | -7.14M | -9.83M | -10.13M | -10.04M |
| Income Tax Expenses | -- | -- | -125.00K | -- | -- |
| Earnings from Continuing Operations | -3.63M | -7.14M | -9.71M | -10.13M | -10.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.63M | -7.14M | -9.71M | -10.13M | -10.04M |
| EBIT | -6.11M | -7.10M | -9.79M | -10.16M | -9.89M |
| EBITDA | -5.60M | -6.63M | -9.35M | -9.75M | -9.48M |
| EPS Basic | -3.50 | -12.16 | -17.07 | -17.87 | -17.82 |
| Normalized Basic EPS | -2.19 | -7.60 | -10.81 | -11.17 | -11.14 |
| EPS Diluted | -3.50 | -12.30 | -17.08 | -18.00 | -17.82 |
| Normalized Diluted EPS | -2.19 | -7.60 | -10.81 | -11.17 | -11.14 |
| Average Basic Shares Outstanding | 1.04M | 587.40K | 568.80K | 566.60K | 563.50K |
| Average Diluted Shares Outstanding | 1.04M | 587.40K | 568.80K | 566.60K | 563.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |